GlassScriptPhysician profile
Daryl W Pierce
NPI 1316919905
$6,942.70
in general payments reported to CMS, 2019-2025
42 companies · $1,795 in 2025
The $1,795 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $57.06 · 2021: $26.19 · 2022: $56.56 · 2023: $1,804 · 2024: $2,789 · 2025: $1,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,060 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,060.10 |
| Education | $327.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $743.82 | 2022-2025 | Calquence, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $546.32 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $467.34 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $444.34 | 2019-2025 | |
| Astellas Pharma US INC | $432.02 | 2023-2025 | Padcev, Vyloy, Xospata |
| Exelixis INC. | $360.11 | 2023-2024 | Cabometyx |
| Pfizer INC. | $339.30 | 2020-2025 | |
| Celgene Corporation | $289.87 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Janssen Biotech, INC. | $285.87 | 2019-2024 | Rybrevant, Tecvayli, Darzalex |
| Regeneron Healthcare Solutions, INC. | $234.36 | 2023-2025 | Libtayo |
| Mirati Therapeutics, INC. | $229.26 | 2023-2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $196.64 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Takeda Pharmaceuticals U.S.A., INC. | $183.36 | 2023-2025 | Ninlaro |
| Genentech USA, INC. | $182.56 | 2019-2025 | Tecentriq, Venclexta, Polivy |
| Lilly USA, LLC | $178.21 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $173.95 | 2024-2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $173.02 | 2024-2025 | |
| Eisai INC. | $161.83 | 2019-2025 | |
| Glaxosmithkline, LLC. | $161.67 | 2023-2025 | Ojjaara, Shingrix, Jemperli |
| Genzyme Corporation | $121.18 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.08 | 2019-2025 | |
| Daiichi Sankyo INC. | $95.09 | 2024-2025 | Injectafer, Enhertu |
| Seagen INC. | $93.16 | 2022-2023 | Tukysa |
| Adaptive Biotechnologies Corporation | $84.43 | 2024-2025 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $82.68 | 2019-2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $68.26 | 2023-2024 | |
| Genmab U.S., INC. | $55.44 | 2023-2024 | Epkinly |
| Beone Medicines USA, INC. | $50.60 | 2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $48.48 | 2025 | Lorbrena, Braftovi, Mektovi |
| Taiho Oncology, INC. | $37.03 | 2019 | |
| Sobi, INC | $36.17 | 2023 | |
| Alexion Pharmaceuticals, INC. | $35.53 | 2023 | Ultomiris |
| Sun Pharmaceutical Industries INC. | $34.41 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $33.73 | 2024 | Onivyde |
| Aveo Pharmaceuticals, INC. | $32.84 | 2025 | |
| Myriad Genetic Laboratories, INC. | $32.69 | 2024 | Precisetumor |
| Pharmaessentia USA Corporation | $23.63 | 2025 | Besremi |
| Agios Pharmaceuticals, INC. | $19.75 | 2024 | |
| Pharmacosmos Therapeutics INC. | $18.84 | 2025 | Monoferric |
| Shield Therapeutics INC | $15.66 | 2025 | |
| Clovis Oncology, INC. | $14.54 | 2021 | |
| Puma Biotechnology, INC. | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.